B-MS extends biologics manufacturing contract with Lonza

By Zachary Brennan contact

- Last updated on GMT

The extension adds a second biologic to Lonza's manufacturing contract
The extension adds a second biologic to Lonza's manufacturing contract

Related tags: Lonza, Bristol-myers squibb

Bristol-Myers Squibb (B-MS) and Lonza on Thursday announced a multi-year expansion of their existing biologics manufacturing agreement. 

The contract, which began in 2003, will be expanded to include the production of commercial quantities of a second unnamed B-MS biologic medicine at Lonza’s mammalian manufacturing facility in Portsmouth, New Hampshire. Financial terms of the agreement were not disclosed.

A B-MS spokesman told BioPharma-Reporter.com that Lonza currently manufactures the active drug ingredient for rheumatoid arthritis treatment Orencia (abatacept) in Portsmouth. Lonza also currently produces clinical supplies of an investigational biologics medicine for B-MS.

 “Our expanded relationship with Lonza is an important example of our global manufacturing strategy to meet anticipated demand for our commercial biologics portfolio and prepare to bring our late-stage clinical assets to patients by supplementing our in-house manufacturing capabilities​,” said Lou Schmukler, President, Global Manufacturing & Supply, B-MS.

B-MS is also increasing its own manufacturing capacity in order to meet current and future demand for its biologics.

With several potential new biologics in our R&D pipeline, we are prudently increasing our biologic manufacturing capacity now in order to help ensure sufficient, long-term supply of our current and future biologic products​,” a B-MS spokesman told us. “This is not a question of capabilities but rather increasing our capacity​.”

B-MS previously selected Samsung Biologics in a 10-year deal to manufacture​ its monoclonal antibody Yervoy for markets outside the US. The companies later expanded that relationship​ to include other unnamed biologics.


In addition to its state- Portsmouth facility, Lonza offers three additional clinical-to-commercial mammalian production facilities in Tuas, Singapore; Porrino, Spain; and Slough, United Kingdom.

Questions were raised​ on whether Lonza would be able to fill its manufacturing capacity after a biosimilar JV with Teva fell through, though Lonza said it remained confident.

"We are pleased to extend our relationship with Bristol-Myers Squibb for the commercial production of their innovative drug-substance​,” said Marc Funk, COO of Lonza’s Pharma & Biotech Segment. “This reinforces Lonza’s mission to support life-saving medicines by being a reliable supplier of Active Pharmaceutical Ingredients (APIs) for our customers with high-quality  commercial GMP manufacturing services delivered to the market​.”

Related news

Show more

Related products

show more

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Related suppliers

Follow us


View more